FINAL PROGRAMME

FIVE NATIONS CONFERENCE

on

HIV and Hepatitis

8–9 December 2014

Queen Elizabeth II Conference Centre

LONDON · UK

12 CPD Credits
Unique Reference No: 90148
Dear Delegate

Welcome to the inaugural Five Nations Conference on HIV and Hepatitis in London, UK. The Conference has been led by a Programme Committee comprising representatives from all partner organisations from France, Germany, Italy, Spain and the UK.

I would like to extend my grateful thanks to the Committee Members for their efforts in preparing an excellent programme for this conference.

We are especially delighted that a number of eminent international speakers are joining us in London to share their latest research and we thank them for their invaluable contributions in helping to make the conference, what promises to be, a great success.

Finally, we would like to thank our sponsors for their support, which assists greatly with the costs incurred in organising this conference.

We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Yours sincerely,

Dr Ranjababu Kulasegaram
Chair, Five Nations Conference Steering Committee
MONDAY 8 DECEMBER

0900–1930 Registration open at QEII Conference Centre
0925–1200 Pre-conference Clinical Course
0925–1200 Pre-conference Nurses’ Course

FIVE NATIONS CONFERENCE

1145–1930 Exhibition open at the QEII Conference Centre
1145–1230 Lunch
1230–1245 Introduction
1245–1345 Janssen Satellite Symposium
1345–1435 Plenary Session 1
1435–1500 Afternoon tea
1500–1545 Clinical case presentations
1545–1615 Invited Lecture 1
1615–1715 Plenary Session 2
1715–1730 Refreshments
1730–1800 Invited Lecture 2
1800–1900 Gilead Sciences Satellite Symposium
1900–1930 Welcome Reception

TUESDAY 9 DECEMBER

0800–1410 Registration and Exhibition open at QEII Conference Centre
0800–0830 Breakfast supported by AbbVie
0830–0930 AbbVie Satellite Symposium
0930–1035 Plenary Session 3
1035–1100 Morning coffee
1100–1200 Plenary Session 4
1200–1300 Plenary Session 5
1300–1410 Lunch and exhibition
1310–1355 Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop
1410–1500 What is in the pipeline?
1500–1615 Plenary Session 6
1615–1655 Two debates
1655–1700 Close

Conference Organiser: Mediscript Ltd, 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD
T: +44 (0)20 8369 5380 | F: +44 (0)20 8446 9194 | E: bhiva@bhiva.org
MONDAY 8 DECEMBER

PRE-CONFERENCE CLINICAL COURSE

SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR

0900–1200  Registration open at QEII Conference Centre

0925–0930  Welcome Address

   Chairs: Dr Sanjay Bhagani, Royal Free Hospital, London, UK
   Professor Karine Lacombe, Hôpital Saint-Antoine, Paris, France

0930–0955  The history and basics of HCV virology

   Professor Carlo-Federico Perno, University of Rome ‘Tor Vergata’, Italy

0955–1020  Clinical evaluation of HCV-induced liver disease

   Professor Karine Lacombe, Hôpital Saint-Antoine, Paris, France

1020–1045  The impact of HIV on hepatitis C and vice versa

   Dr Sanjay Bhagani, Royal Free Hospital, London, UK

1045–1110 Morning coffee

1110–1135  Treatment of hepatitis C: who, when and how

   Dr Patrick Ingiliz, Medical Center for Infectious Diseases, Berlin (MIB), Germany

   Panel:
   Mr Siegfried Schwarze, Medical European AIDS Treatment Group (EATG)

1135–1200  End-stage liver disease and its complications

   Professor Graham Foster, Queen Mary University of London, UK

Pre-conference Clinical Course

is sponsored by

Bristol-Myers Squibb

Bristol-Myers Squibb has supported this Pre-conference Clinical Course by purchasing exhibition stand space and delegate places and has had no input into the selection of speakers or topics
MONDAY 8 DECEMBER

PRE-CONFERENCE NURSES’ COURSE

SESSIONS TO BE HELD IN THE CAXTON EAST ROOM, SECOND FLOOR

0900–1200
Registrations open at QEII Conference Centre

0925–0930
Welcome Address
Chairs: Ms Michelle Croston, National HIV Nurses Association (NHIVNA)
       Ms Fiona Fry, Chair, British Association for the Study of the Liver Nurse Forum (BASLNF)

0930–0955
Understanding the hepatitis C virus: a nurse perspective
Mr Dean Linzey, Royal Berkshire NHS Foundation Trust, Reading, UK

0955–1020
A guide to the anatomy and physiology of the liver
Ms Amanda Clements, Plymouth Hospital NHS Foundation Trust, UK

1020–1045
Introduction to blood results, interpretation and nursing priorities
Mrs Janet Catt, Royal Free London NHS Foundation Trust, UK

1045–1110
Morning coffee

1110–1135
How will new treatments affect nursing practice?
Mr Ricky Gellissen, Imperial College Healthcare NHS Trust, London, UK

1135–1200
What is the impact of HIV/HCV co-infection in the era of chem sex?
Mr Joe Phillips, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

The Pre-conference Nurses’ Course is organised by the National HIV Nurses Association (NHIVNA) and the British Association for the Study of the Liver Nurses’ Forum (BASLNF)

Sponsors have supported this Course by purchasing exhibition stand space and delegate places and have had no input into the course programme
**MONDAY 8 DECEMBER**

**FIVE NATIONS CONFERENCE**

**SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1145–1930</td>
<td>Registration and Exhibition open at QEII Conference Centre</td>
</tr>
<tr>
<td>1145–1230</td>
<td>Lunch</td>
</tr>
<tr>
<td>1230–1245</td>
<td><strong>Introduction and Welcome</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Ranjababu Kulasegaram, Chair, Five Nations Conference Steering Committee</td>
</tr>
<tr>
<td></td>
<td>Panel</td>
</tr>
<tr>
<td></td>
<td>Professor Karine Lacombe, French National Agency for AIDS Research (ANRS)</td>
</tr>
<tr>
<td></td>
<td>Dr Juan Pineda, Spanish Infectious Diseases and Clinical Microbiology Society (SEIMC)</td>
</tr>
<tr>
<td></td>
<td>Professor Jürgen Rockstroh, German AIDS Society (DAIG)</td>
</tr>
<tr>
<td></td>
<td>Professor Gloria Taliani, Italian Society of Infectious and Tropical Diseases (SIMIT)</td>
</tr>
<tr>
<td></td>
<td>Dr Andrew Ustianowski, British Association for the Study of the Liver (BASL)</td>
</tr>
<tr>
<td>1245–1345</td>
<td><strong>Janssen Satellite Symposium</strong> (see page 10 for further details)</td>
</tr>
<tr>
<td>1345–1435</td>
<td><strong>Plenary Session 1</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Juan Berenguer, Hospital General Universitario Gregorio Marañón, Madrid, Spain</td>
</tr>
<tr>
<td></td>
<td>Dr Graham Cooke, Imperial College, London, UK</td>
</tr>
<tr>
<td></td>
<td>The global challenge of HCV</td>
</tr>
<tr>
<td></td>
<td>Dr Isabelle Andrieux-Meyer, Médecins Sans Frontières, Geneva, Switzerland</td>
</tr>
<tr>
<td></td>
<td>The epidemiology of HIV and viral hepatitis in Europe</td>
</tr>
<tr>
<td></td>
<td>Professor Amanda Mocroft, Institute of Epidemiology and Health, London, UK</td>
</tr>
<tr>
<td>1435–1500</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1500–1545</td>
<td><strong>Clinical case presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Gary Brook, North West London Hospitals NHS Trust, UK</td>
</tr>
<tr>
<td></td>
<td>Dr Janice Main, Imperial College Healthcare NHS Trust, London, UK</td>
</tr>
<tr>
<td></td>
<td>Panel</td>
</tr>
<tr>
<td></td>
<td>Dr Manuel Crespo, Vall d’Hebron Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td></td>
<td>Professor Lionel Piroth, CHU Dijon, France</td>
</tr>
<tr>
<td></td>
<td>Professor Massimo Puoti, University of Brescia, Italy</td>
</tr>
<tr>
<td></td>
<td>Dr Christopher Taylor, King’s College Hospital NHS Foundation Trust, London, UK</td>
</tr>
<tr>
<td></td>
<td>Once, twice, three times a virus …</td>
</tr>
<tr>
<td></td>
<td>Dr Binta Sultan, Mortimer Market Centre, London, UK</td>
</tr>
<tr>
<td></td>
<td>Renal impairment during triple therapy with telaprevir for chronic hepatitis C: a case report</td>
</tr>
<tr>
<td></td>
<td>Dr Elisa Biliotti, Sapienza University of Rome, Italy</td>
</tr>
<tr>
<td></td>
<td>Hepatitis delta is leading infection in HBV/HCV/HDV and HIV patient</td>
</tr>
<tr>
<td></td>
<td>Dr Ivana Carey, King’s College Hospital, London, UK</td>
</tr>
</tbody>
</table>
MONDAY 8 DECEMBER

FIVE NATIONS CONFERENCE

1545–1615  **Invited Lecture 1**
Chair: Dr Kosh Agarwal, King’s College Hospital NHS Trust, London, UK
Liver transplantation in the HIV-infected population
Professor Massimo Puoti, University of Brescia, Italy

1615–1715  **Plenary Session 2**
Chairs: Professor Jürgen Rockstroh, University of Bonn, Germany
Dr Andrew Ustianowski, North Manchester General Hospital, UK

Extrahepatic manifestations of HCV: from immune- to inflammation-related manifestations
Professor Patrice Cacoub, La Pitié-Salpêtrière Hospital, Paris, France

Non-alcoholic steatohepatitis (NASH)
Dr Maud Lemoine, Imperial College Healthcare NHS Trust, London, UK

1715–1730  **Refreshments (Churchill Auditorium, Ground Floor)**

1730–1800  **Invited Lecture 2**
Chair: Dr Emma Page, Leeds Teaching Hospitals Trust, UK
Hepatocellular carcinoma
Dr Nicolás Merchante, Hospital Universitario de Valme, Sevilla, Spain

1800–1900  **Gilead Sciences Satellite Symposium**
(see page 10 for further details)

1900–1930  **Welcome Reception**
Pickwick Suite, First Floor

1945–2200  **Janssen Evening Seminar: The ART of HIV**
One Great George Street, London
The evening seminar is not part of the formal Five Nations Conference programme, but delegates are welcome to attend. See delegate bag insert for further details.
# FIVE NATIONS CONFERENCE

## SESSIONS TO BE HELD IN THE CHURCHILL AUDITORIUM, GROUND FLOOR

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–1615</td>
<td>Registration and Exhibition opens at QEII Conference Centre</td>
</tr>
<tr>
<td>0800–0830</td>
<td>Breakfast sponsored by AbbVie</td>
</tr>
<tr>
<td>0830–0930</td>
<td>AbbVie Satellite Symposium (see page 10 for further details)</td>
</tr>
<tr>
<td>0930–1035</td>
<td>Plenary Session 3&lt;br&gt;Chairs: Dr Ashley Brown, Imperial College Healthcare NHS Trust, London, UK&lt;br&gt;Dr Mark Nelson, Chelsea and Westminster Hospital, London, UK&lt;br&gt;Treatment of HCV in mono-infected patients&lt;br&gt;Professor Jean-Michel Pawlotsky, Hôpital Henri Mondor, Paris, France&lt;br&gt;Treatment of HCV in co-infected patients&lt;br&gt;Professor Douglas Dieterich, Mount Sinai Medical Center, NYC, USA&lt;br&gt;Panel discussion</td>
</tr>
<tr>
<td>1035–1100</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1100–1200</td>
<td>Plenary Session 4&lt;br&gt;Chairs: Professor Francesca Ceccherini-Silberstein, University of Rome ‘Tor Vergata’, Italy&lt;br&gt;Dr Juan Macia, Hospital Universitario de Valme, Sevilla, Spain&lt;br&gt;What’s new in hepatitis B/HIV co-infection?&lt;br&gt;Professor Vincent Soriano, Hospital Carlos III, Madrid, Spain&lt;br&gt;Will hepatitis B become a curable disease?&lt;br&gt;Dr Patrick Kennedy, The Royal London Hospital, UK</td>
</tr>
<tr>
<td>1200–1300</td>
<td>Plenary Session 5&lt;br&gt;Chairs: Dr Stefan Mauss, Centre for HIV and Hepatogastroenterology, Düsseldorf, Germany&lt;br&gt;Dr Emma Thomson, University of Glasgow, UK&lt;br&gt;Hepatitis D in HIV&lt;br&gt;Dr Kate Childs, King’s College Hospital NHS Foundation Trust, London, UK&lt;br&gt;Acute hepatitis C&lt;br&gt;Dr Emma Page, Leeds Teaching Hospitals Trust, UK</td>
</tr>
<tr>
<td>1300–1410</td>
<td>Lunch and exhibition</td>
</tr>
<tr>
<td>1310–1355</td>
<td>Bristol-Myers Squibb Pharmaceuticals Limited Lunchtime Workshop&lt;br&gt;Caxton East Room, Second Floor&lt;br&gt;Lunchpacks will be provided (see page 10 for further details)</td>
</tr>
</tbody>
</table>
FIVE NATIONS CONFERENCE

1410–1500 What is in the pipeline?
Chairs: Professor Clifford Leen, Western General Hospital, Edinburgh, UK
Dr Ed Wilkins, North Manchester General Hospital, UK
Dr Alice Butler, AbbVie Ltd
Dr Adyb Baakili, Bristol-Myers Squibb Pharmaceuticals Ltd
Dr Cham Herath, Gilead Sciences International Ltd
Dr Jonty Manuja, Janssen
Dr Andrew Wilfin, MSD Ltd

1500–1615 Plenary Session 6
HIV/hepatitis in Europe: who, when and where
Chairs: Dr Ranjababu Kulasegaram
Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Mr Brian West, European AIDS Treatment Group (EATG)

United Kingdom
Professor Caroline Sabin, Royal Free and University College Medical School, London, UK

France
Professor Lionel Piroth, CHU Dijon, France

Germany
Dr Christoph Boesecke, University of Bonn, Germany

Italy
Professor Gloria Taliani, Sapienza University of Rome, Italy

Spain
Dr Juan Pineda, Hospital Universitario de Valme, Sevilla, Spain

European AIDS Treatment Group (EATG)
Mr Diego Garcia Morcillo, European AIDS Treatment Group (EATG), Spain

Panel discussion

1615–1655 Two debates:
Chairs: Mr Maxime Journiac, European AIDS Treatment Group (EATG)
Dr Daniel Webster, Royal Free London NHS Foundation Trust, UK

• Re-infections should not be retreated
For the motion: Dr Robert James, Birchgrove, UK
Against the motion: Mr Luís Mendão, European AIDS Treatment Group (EATG), Portugal

• F2–F3 fibrosis: treat now
For the motion: Professor Jürgen Rockstroh, University of Bonn, Germany
Against the motion: Dr Mark Nelson, Chelsea and Westminster Hospital, London, UK

1655–1700 Close
Dr Ranjababu Kulasegaram, Chair, Five Nations Conference Steering Committee
# Programme of Satellite Symposia and Sponsors Lunchtime Workshop

All Satellite Symposia will be held in the Churchill Auditorium, Ground Floor. Lunchtime Workshops will be held in the Caxton East Room, Second Floor.

## MONDAY 8 DECEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 1245–1345 | **Janssen Satellite Symposium** | **HIV and hepatitis C: the patient’s journey through a clinical setting**  
Chair: Dr Emma Page, Leeds Teaching Hospitals NHS Trust  
Dr Laura Waters, University College London Medical School, UK  
Dr Ed Wilkins, North Manchester General Hospital, UK |
| 1800–1900 | **Gilead Sciences Satellite Symposium** | **Transforming HCV care: learning from the HIV journey**  
Defining the challenges – back to the future  
Professor Jürgen Rockstroh, University of Bonn, Germany  
Charting success – lessons learned from HIV  
Professor Karine Lacombe, Hôpital Saint-Antoine, Paris, France  
Quantum leaps forward – transforming HCV care  
Dr Andrew Ustianowski, North Manchester General Hospital, UK  
Overcoming the challenges – fast-forward to the future  
Panel discussion |

## TUESDAY 9 DECEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 0830–0930 | **AbbVie Satellite Symposium** | **Striving for clarity in HIV/HCV co-infection: defining priorities via Room 101**  
Chair: Dr Laura Waters, University College London Medical School, UK  
Dr Kosh Agarwal, King’s College Hospital, UK  
Dr Sanjay Bhagani, Royal Free London NHS Foundation Trust, UK  
Dr Mark Nelson, Chelsea and Westminster Hospital, UK |
| 1310–1355 | **Bristol-Myers Squibb Pharmaceuticals Limited Lunchtime Workshop** | **Cases from the clinic: New options for patients with hepatitis C**  
Chair: Dr Mark Nelson, Chelsea and Westminster Hospital, London, UK  
Dr Ashley Brown, Imperial College Healthcare NHS Trust, London, UK  
Dr Andrew Ustianowski, North Manchester General Hospital, UK |
Registration

FIVE NATIONS CONFERENCE  The registration fee gives access to the scientific sessions of the Five Nations Conference on HIV and Hepatitis including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee. Registration opens from 1145 on Monday 8 December and from 0800 on Tuesday 9 December 2014.

PRE-CONFERENCE COURSES: Clinical Course and Nurses’ Course  Registration is on a complimentary basis. However, if you fail to turn up to the event, then your cheque or credit card will be charged £50. Registration gives access to the scientific sessions of the relevant course. Welcome and mid-morning refreshments are included. Please note that lunch is not included as part of registration for the courses. Registration for the courses opens from 0900 on Monday 8 December 2014.

WELCOME RECEPTION  The Welcome Reception immediately follows the conference programme at 1900–1930 on Monday 8 December and will take place in the Exhibition area located in the Pickwick Suite, first floor.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to received CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

<table>
<thead>
<tr>
<th>CPD Accreditation</th>
<th>Credits attributed</th>
<th>Unique ref number</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIVE NATIONS CONFERENCE ON HIV AND HEPATITIS</td>
<td>10 Credits</td>
<td>90148</td>
</tr>
<tr>
<td>PRE-CONFERENCE CLINICAL COURSE</td>
<td>2 Credits</td>
<td>90148</td>
</tr>
<tr>
<td>PRE-CONFERENCE NURSES’ COURSE</td>
<td>2 Credits</td>
<td>90148</td>
</tr>
</tbody>
</table>

Accommodation

Please note that the registration fee does not include accommodation. A list of hotels and rates is available on the BHIVA website (www.bhiva.org). Please note that HotelMap has been appointed the official conference accommodation bureau. HotelMap is a web-based service that provides live details of hotel deals directly from hotels near to our event venue. On booking, you will receive a hotel reservation booking reference number. Payment will need to be made by you, directly to the hotel.

Book online: www.bhiva.org · Queries: HotelMap · Tel: 0207 420 4987

Cloakroom

A staffed Cloakroom is available at the Queen Elizabeth II Conference Centre. All belongings are left at the owner’s risk. The Queen Elizabeth II Conference Centre and the British HIV Association do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom areas.

Conference venue  Queen Elizabeth II Conference Centre

Broad Sanctuary · Westminster · London SW1P 3EE · +44 (0)20 7222 5000 · qeiicc.co.uk

The conference venue is a short walk from Westminster or St James’s Park underground stations. Please see the map for the location of these stations in relation to the Queen Elizabeth II Conference Centre. Westminster and St James’s Park underground stations are easily accessible from King’s Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James’s Park underground stations takes approximately 10 minutes and costs approximately £4.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk

Please note that the conference venue is located within the London Congestion Charge Zone.
Sponsors and Exhibitors

CONFERENCE SPONSORS

AbbVie Limited
Abbott House, Vanwall Business Park
Maidenhead
Berkshire SL6 4XE

Boehringer Ingelheim Limited
Ellesfield Avenue
Bracknell
Berkshire RG12 8YS

Bristol-Myers Squibb Pharmaceuticals Limited
Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH

Gilead Sciences Limited
Granta Park
Great Abington
Cambridgeshire CB21 6GT

Janssen
50–100 Holmers Farm Way
High Wycombe
Buckinghamshire HP12 4EG

MSD Limited
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU

CONFERENCE EXHIBITORS

Commercial

Bristol-Myers Squibb Pharmaceuticals HCV

Cepheid

Hologic

Janssen HIV

Educational and Charitable

European AIDS Treatment Group (EATG)

UK Community Advisory Board (UK-CAB)

PRE-CONFERENCE COURSES

Pre-conference Clinical Course

Bristol-Myers Squibb Pharmaceuticals has supported the Five Nations Pre-conference Clinical Course by purchasing exhibition stand space and delegate places and has had no input into the selection of speakers or topics.

Pre-conference Nurses’ Course

AbbVie, Gilead Sciences, Janssen and Roche have supported the Five Nations Pre-conference Nurses’ Course by purchasing exhibition stand space and delegate places and have had no input into the course programme.
**KEY TO EXHIBITORS**

Stand 1 .................................................... AbbVie
Stand 2 .................................................... MSD
Stand 3 .................................. Bristol-Myers Squibb Pharmaceuticals (HCV)
Stand 4 .................................. European AIDS Treatment Group (EATG)
Stand 5 .................................. UK Community Advisory Board (UK-CAB)
Stand 6 ........................................ Hologic
Stand 7 ........................................ Cepheid
Stand 8 ........................................ Gilead Sciences
Stand 9 .................................. Bristol-Myers Squibb Pharmaceuticals (HIV)
Stand 10 .................................. Janssen (HCV)
Stand 11 .................................. Janssen (HIV)
Programme Committee and Partner Organisations

FIVE NATIONS PROGRAMME COMMITTEE

Dr Mark Nelson (Chair) Chelsea and Westminster Hospital, London, UK
Dr Sanjay Bhagani (BHIVA) Royal Free Hospital, London, UK
Professor Giovanni Guaraldi (SIMIT) University of Modena, Italy
Dr Mark Hudson (BASL) Freeman Hospital, Newcastle, UK
Dr Robert James (UK-CAB) Birchgrove, Brighton, UK
Mr Damian Kelly (EATG) George House Trust, Manchester, UK
Dr Ranjababu Kulasegaram (BHIVA) St Thomas’ Hospital, London, UK
Professor Karine Lacombe (ANRS) Hôpital Saint-Antoine, Paris, France
Professor Clifford Leen (BHIVA) Western General Hospital, Edinburgh, UK
Dr Alastair Miller (BHIVA) Royal College of Physicians, London, UK
Dr Juan Macias (GEHEP) Hospital Universitario de Valme, Sevilla, Spain
Dr Stefan Mauss (DAIG) Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Dr Juan Antonio Pineda (GEHEP) Hospital Universitario de Valme, Sevilla, Spain
Professor Lionel Piroth (ANRS) Centre Hospitalier Universitaire, Dijon, France
Professor Jürgen Rockstroh (DAIG) University of Bonn, Germany
Professor Gloria Taliani (SIMIT) Sapienza University of Rome, Italy
Dr Andrew Ustianowski (BVHG) North Manchester General Hospital, UK
Biographies

Isabelle Andrieux-Meyer  MD is an HIV and viral hepatitis specialist with Médecins sans Frontières. She works on clinical and programmatic issues relating to access to diagnostics and antiretroviral therapy, and viral hepatitis oral treatments in resource-limited settings. She serves also as Médecin Visitant at Geneva University Hospital, at the Infectious Disease Consultation.

Sanjay Bhagani  is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free London NHS Foundation Trust. He has a special interest in the management of complex HIV infection, including difficult opportunistic infections and the management of viral hepatitis in HIV-infected patients.

Christoph Boesecke  MD completed his medical studies at Charité University in Berlin, Germany. He received his Doctorate in Medicine from the University of Hamburg, Germany for his research on acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now the Kirby Institute) in Sydney, Australia. He is currently working as an Infectious Diseases Specialist and Clinical Research Fellow at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV, particularly acute hepatitis C.

Patrice Cacoub  is Professor in Internal Medicine at the Pierre and Marie Curie University (PMCU) in Paris, France. He is also Head of the Department of Internal Medicine at La Pitié-Salpêtrière Hospital in Paris. His research focuses on autoimmune diseases, HCV, HBV, HIV, peripheral neuropathies, anaemia and vascular medicine, and he has authored more than 500 research publications, 52 books and 120 CME publications in these fields. Professor Cacoub is currently a reviewer for many top-ranked journals. The recipient of several awards, including the Fred Siguier Award of the French National Society of Internal Medicine, Professor Cacoub has been involved in the development of a number of national and international guidelines, clinical trials and initiatives to improve clinical care, particularly in HCV treatment and HIV/HCV co-infection, and in peripheral arterial disease.

Janet Catt  MSc RGN, Independent Non-medical Prescriber, has had a varied nursing experience that has included oncology, haematology, palliative care and health visiting. Since 2008 she has been a Lead Nurse Specialist Practice at the Royal Free Hospital, London where she manages a team of clinical nurse specialists and leads on the development of the nursing service. As part of her role, she also researches local epidemiology in order to develop ways to improve patient pathways. She is a founder member of the steering group for the Interactive Summit on Hepatitis and sits on the London Joint Working Group for Substance Misuse and Hepatitis C. She is a regular speaker at international conferences.

Kate Childs is currently undertaking a PhD on HIV and hepatitis as an NIHR Doctoral Fellow at King’s College London. She attained her undergraduate degree from St Hugh’s College, Oxford and medical qualification from University College Hospital, London. She completed her specialist training in genitourinary medicine at King’s College Hospital where she has been involved in the HIV/hepatitis co-infection clinic since 2009.

Amanda Clements  MSc, PGCE, PGDip is an Advanced Nurse Practitioner, Independent Non-medical Prescriber and Hepatology Nurse Consultant for the South West Liver Unit, Derriford Hospital, Plymouth. She has been in post for over 14 years and during this time, the hepatology nursing service has rapidly expanded, reflecting the growth of liver disease. Her particular area of interest is promoting and developing end-of-life and long-term condition management for individuals and their care-givers, affected by end-stage liver disease. Amanda is chief editor for the BASL Nurse e-learning toolkits and she has been actively involved with the BASL Nurse Forum since it first began.

Douglas T Dieterich is currently Professor of Medicine in the Division of Hepatology, New York, NY with a triple appointment in the divisions of Liver Disease, Gastroenterology and Infectious Diseases. He is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B and C. Professor Dieterich is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis. Widely published, he is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver.
Biographies

Graham Foster is the Professor of Hepatology at Queen Mary University of London and a consultant at Barts Health in East London. He trained in medicine at Oxford and London Universities and completed a PhD in molecular biology in 1992. He has a long-standing interest in the management of chronic viral hepatitis and runs a clinical research programme studying the natural history of viral hepatitis, its impact upon individuals and their communities, and novel therapies for this disease. He leads a national study investigating community screening for viral hepatitis and supervises a laboratory research programme investigating novel replication models for hepatitis C. He is the editor of Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is a past President of BASL, Vice Chair of the UK Department of Health Advisory Group on Hepatitis, and a member of a number of patient advocacy groups.

Diego Garcia Morcillo is currently Chair of a community centre for HIV/AIDS and other STIs in Seville, Spain and also the Coordinator of the Spanish CAB-FEAT. He lives with HIV and hepatitis C and since 2009, he has been a community representative on the EACS co-infection panel.

Ricky Gellissen has worked in HIV nursing since the early 1990s. Since 2008 he has been an HIV and hepatitis co-infection Clinical Nurse Practitioner, working across the HIV and Hepatology departments. He holds clinics in both departments seeing HIV or hepatitis mono-infected patients, but his primary focus is on managing HCV treatments for the HIV/HCV co-infected patients, including those on the NHS England-funded expanded-access programme.

Patrick Ingiliz is a specialist in Internal Medicine and Infectious Diseases. He is a consultant at the Medical Center for Infectious Diseases in Berlin. His clinical research projects are focused on acute hepatitis C infection, liver fibrosis progression and steatohepatitis in HIV infection. He is actively involved in numerous trials on directly acting agents against hepatitis C in mono- and co-infected subjects.

Robert James is a sessional lecturer at the School of Law, Birkbeck College, and a patient rep at the HIV clinic in Brighton UK. He is the community member of the BHIVA Hepatitis Coinfection Guidelines writing group.

Patrick Kennedy is a Senior Lecturer and Consultant Hepatologist at Barts and The London School of Medicine and Dentistry. His research focus is in hepatitis B and particularly immunopathogenesis of disease in young people. In addition, he has served on the NICE clinical guideline development group for chronic hepatitis B and most recently was a member of the NICE Quality Standards committee.

Ranjababu Kulasegaram is a Consultant in HIV/GU Medicine at St Thomas’ Hospital and leads the HIV Treatment Advice Clinic. He has special interests in HIV/hepatitis, haemophilia/HIV infection, HIV/neurocognitive function and HIV inpatient management. He is committed to enhancing BHIVA’s educational activities through his involvement as Vice Chair of the BHIVA Educational and Scientific subcommittee, member of the Conferences subcommittee and E-Learning working group. He is also Chair of the BHIVA Hepatitis Society and an examiner for the Diploma in HIV Medicine.

Karine Lacombe MD, PhD is Associate Professor at the Medical School of the Pierre and Marie Curie University, Paris, attached to the Infectious and Tropical Diseases department of Saint-Antoine Hospital, Paris. She is involved in clinical research in Europe, Sub-Saharan Africa and Vietnam on the issues of HIV-chronic hepatitis B and C, as well as co-morbidities associated with the use of antiretrovirals.

Maud Lemoine is a Clinical Senior Lecturer and Honorary Consultant in Hepatology at St Mary’s Hospital, Imperial College London. She completed her medical degree and a PhD in physiology and physiopathology in Paris. She also graduated in political sciences from the Institute of Political Studies in Paris. She has spent the last two years at the Medical Research Council (MRC) Laboratories in The Gambia, West Africa running the PROLIFICA project (EU-FP7) on HBV and liver cancer. She is the Chief investigator of the multicentric European study on metabolic liver disease in HIV (ECHAM study funded by ANRS-HIVERA). She is member of the WHO scientific advisory board for the development of hepatitis C guidelines and a member of the French Research Agency on HIV/AIDS and viral hepatitis (ANRS).
Biographies

Dean Linzey is Nurse Consultant for viral hepatitis at the Royal Berkshire Hospital. He is a counsellor and holds an MA in Psychoanalytic Studies. He is an Independent Non-medical Prescriber and Chair of the South regional Viral Hepatitis Nurses group. He has focused on blood-borne viruses for more than 20 years, working in UK clinics and abroad. He developed HIV counselling training for the UN in India and has worked for the British Council, CDC and Médecins Sans Frontières in Russia, Ukraine, Kenya, Tanzania, Uganda and Malawi. His particular interest is in community capacity building in relation to blood-borne viruses. Dean developed the BBV Champions project in 2010 for which he was awarded Gastrointestinal Nurse of the year in 2012; he was also awarded ‘Healthcare worker of the year’ in the 2012 Pride of Reading awards.

Luís Mendão concluded his studies in biochemistry in 1983 at the Pierre and Marie Curie University, Paris. He is currently Chair of GAT-Pedro Santos, an NGO founded in 2001 that works in the areas of prevention, early diagnosis, and treatment and care of HIV/AIDS and related diseases for most at-risk groups. He is also the founder and a member of the Board of Directors of the AntiProhibitionist Association, SOMA-APA. He represents Portugal in the Civil Society Forum on HIV/AIDS at the European Commission, is a member and Vice Chair of the European AIDS Treatment Group (EATG) and is also on the Steering Committee of the HIV Portugal Initiative. In the last 10 years, he has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC. Luís Mendão was diagnosed with HIV and HCV in 1996.

Nicolás Merchante works at the Infectious Diseases unit of the Hospital Universitario de Valme, Seville. As a clinical investigator, he has focused on the natural history of cirrhosis, end-stage liver disease and hepatocellular carcinoma in the setting of HIV/HCV-co-infected individuals. He is the coordinator of the GEHEP multicentre collaborative national cohort of hepatocellular carcinoma in HIV-infected patients in Spain.

Amanda Mocroft has worked in HIV epidemiology and biostatistics based at University College London since 1993. Particular interests include cohort studies and long-term outcomes of HIV infection, including mortality and non-AIDS-defining events, such as renal disease and malignancies. She is the co-PI of EuroSIDA, one of the largest multinational European cohorts of HIV-infected persons, and is also involved in numerous other cohort studies, including Data on Adverse Events (D:A:D), Antiretroviral Therapy Cohort (ART-CC), COHERE and MATCH. With over 200 publications, she has extensive experience with data collection, design and analyses of cohort studies, and nested case control studies using sample repositories.

Mark Nelson is a Consultant Physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital Medical School from where he qualified in 1986. He is presently the lead for HIV in-patient and day-case care and is an Adjunct Professor in Human Immunodeficiency Virology at Imperial College Medical School where he is also the deputy senior tutor. He is now devoting most of his charitable time to the Green Shoots Foundation where he is establishing HIV treatment networks in Burma and Vietnam. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and Mbale Medical School, Uganda and most recently, was awarded the Certificate of Merit by the Government of Vietnam.

Emma Page is currently a locum Consultant in GUM and Virology at Leeds Teaching Hospitals Trust with a subspecialty interest in HIV and hepatitis co-infection. She trained at Chelsea and Westminster Hospital and has an MD(Res) from Imperial College London in the immunology of HIV and hepatitis C co-infection.

Jean-Michel Pawlotsky MD, PhD is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri Mondor University Hospital, Créteil, France. He is also Director of the Viruses, Immunity and Cancers Academic Department, INSERM U955. He was Secretary General of EASL, an Associate Editor of Hepatology and is currently an Associate Editor of Gastroenterology. He has published over 450 articles and book chapters and regularly lectures at international meetings.

Carlo-Federico Perno is Professor of Virology at the University of Rome ‘Tor Vergata’, and Director of the Unit of Molecular Virology at the Tor Vergata University Hospital, Rome. He is also a Consultant in Clinical Virology at the Spallanzani Hospital for Infectious Diseases, Rome. He gained his MD from the University of Rome. During his time as a Research Fellow at the National Cancer Institute, Bethesda (1986–1989), he collaborated in the discovery and clinical application of the first antiviral drugs used in the therapy of HIV infection, including zidovudine, zalcitabine, stavudine and didanosine. He has published more than 400 international scientific articles and in 2001, was presented with a Descartes Award for excellence in the antiviral field by the European Community. His major expertise is in antiviral therapy, clinical interpretation and therapeutic application of antiviral resistance testing and he leads a group of internationally recognised researchers.
Joe Phillips has worked in the field of HIV for around 10 years, both as a nurse and within the voluntary sector. After starting his career at the Infectious Diseases Unit, North Manchester Hospital he worked in the North-west as both an HIV and hepatitis C Specialist Nurse. He is currently employed as a Nurse Practitioner at 56 Dean Street in central London and has a specialist interest in HIV/hepatitis C co-infection, especially in relation to gay men who use chems for sex.

Juan A Pineda earned his medical degree and PhD at the University of Seville. He completed his training in the Virgen del Rocío University Hospital in Seville and in the Presbyterian Hospital, Pittsburgh, USA. He is a Consultant in viral hepatitis and HIV infection in the Infectious Diseases Unit of the Valme University Hospital, Associate Professor of Medicine at the University of Seville, and Head of the Viral Hepatitis Study Group of the Spanish Society for Infectious Diseases and Clinical Microbiology.

Lionel Piroth has been involved in clinical care and research in HIV and hepatitis viruses in France since the mid-1990s. He is Professor of Infectious Diseases at the University of Burgundy and Physician at the Dijon Hospital, and also actively participates in trials of antiretrovirals and other anti-infective agents. He has been a co-author on the French recommendations for the management of hepatitis co-infection in people living with HIV.

Massimo Puoti is a Specialist in Gastroenterology and Infectious Disease and since November 2010 has been Director of the Infectious Diseases Department of the AO Ospedale Niguarda Cá Granda, the largest hospital in Milan, Italy. His main fields of research are hepatitides viruses and HIV infection.

Jürgen Rockstroh MD is Professor of Medicine and Head of the HIV Outpatient Clinic at the University of Bonn, Germany. In addition to his clinical practice, Professor Rockstroh is involved in HIV research on: antiretroviral therapy, including new drug classes; the course of HIV disease in haemophiliacs; and HIV and hepatitis co-infection. He has been an investigator in multiple clinical trials of antiretroviral agents and treatments for HIV and hepatitis co-infection.

Caroline Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL) and is Director of the National Institutes for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, a partnership between UCL, Public Health England (PHE) and the London School of Hygiene and Tropical Medicine. She has worked for many years on the analysis of large observational HIV databases with a particular interest in raising awareness of the biases inherent in these databases; she is the principal investigator on the UK CHIC Study, the principal statistician on the D:A:D Study, co-principal investigator on the POPPY Study, and has worked with many other research groups in the UK and elsewhere.

Vincent Soriano MD PhD received his medical degree in Barcelona, and subsequently specialised in Internal Medicine. After a post-doctoral post at the FDA, Bethesda, USA, he returned to Spain and joined the Infectious Diseases Department at Hospital Carlos III in Madrid. His expertise is mainly focused on HIV and viral hepatitis.

Gloria Taliani DM, PhD is Professor of Infectious Diseases and Director of the School of Tropical Medicine, Sapienza University of Rome. She previously held the position of Director of the Clinic of Infectious Diseases, University of Florence. Her main area of scientific interest is viral hepatitis.

Andrew Ustianowski is a Consultant Physician in Infectious Diseases and Tropical Medicine at the Regional Infection Unit, North Manchester General Hospital, which has a cohort of around 2000 HIV-positive individuals. He has been part of guideline writing groups for BHIVA and other bodies, is chair of the British Viral Hepatitis Group, and is on the national CRGs for hepatitis C and infectious diseases. He also lectures widely on HIV, hepatitis and related topics, and is part of several national and international educational steering groups. He graduated from Guy’s Hospital, London, and subsequently trained in Infectious Diseases, HIV and General Medicine in the London region.
WITH DAKLINZA® AS YOUR ALLY, YOU CAN ACHIEVE...

NOW APPROVED

THE LONG-AWAITED RESPONSE

Introducing Daklinza, a potent, pan-genotypic (in vitro) NS5A inhibitor with clinical efficacy in genotypes 1-4, which cures the vast majority of patients with chronic hepatitis C virus (HCV) including:1,2,4

ADVANCED FIBROSIS | PI FAILURES | GENOTYPE 3

Genotypes 1 & 3 treatment-naive

100% EFFICACY

n=66

100% EFFICACY

n=41

89% EFFICACY

n=18

Daklinza is indicated in combination with other medicinal products for the treatment of chronic HCV infection in adults.1 Daklinza must not be administered as monotherapy.1

* Cure is defined as an undetectable HCV RNA at 24 weeks (lower limit of detection <15 IU/mL, SWR) which has a 99% concordance with SR, as the definitive cure of HCV infection.2

† Vast majority based on UK epidemiology corresponding to 90% of HCV patients with genotype 1 or genotype 3.2

‡ Advanced fibrosis is defined as a score of F3 based on FibroTest data. The METAIR score was derived from the FibroTest Score and cut-off according to the manufacturer’s instructions (www.biopredictive.com); patients with a score of F4 were required to have no evidence of cirrhosis on the basis of a liver biopsy.2

© 2014 Bristol-Myers Squibb Company 1392X14PR9582-01 November 2014.

Daklinza® is a registered trademark of Bristol-Myers Squibb and its affiliates.

References:
1. DAKLINZA (daclatasvir) prescribing information. See Summary of Product Characteristics before prescribing.